The ASCO Post captured initial reactions to the Oncologic Drugs Advisory Committee (ODAC) recommendation that the breast cancer indication for bevacizumab (Avastin) be revoked in interviews with ODAC voting members, breast cancer specialists, oncologists in private practice, third-party payers, and a patient advocate. These reactions are available here at ASCOPost.com and in the September print issue of The ASCO Post.

(Photos, L to R: Sandra M. Swain, MD; Harold J. Burstein, MD; Wyndham Wilson, MD, PhD; Edith A. Perez, MD; Matthew Ellis, MD, BChir, PhD; Kathy S. Albain, MD, FACP; Musa Mayer; Steven Vogl, MD; Joanne Mortimer, MD; Cary Presant, MD, FACP; Eric P. Winer, MD)

Bevacizumab, ODAC, and the FDA, by Gabriel Hortobagyi, MD

ODAC Voting Members Discuss Panel's Recommendation about Bevacizumab in Advanced Breast Cancer, by Wyndham Wilson, MD, PhD, and Joanne Mortimer, MD

Nine Members of the Oncology Community Speak Out about Bevacizumab's Role in Metastatic Breast Cancer, Compiled by Caroline Helwick

For Bevacizumab, Third-party Payers Look to NCCN, by Caroline Helwick

Answering Questions Your Patients May Ask about the Role of Bevacizumab in Metastatic Breast Cancer, by Charlotte Bath